These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26862736)

  • 41. VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.
    Barr MP; O'Byrne KJ; Al-Sarraf N; Gray SG
    Epigenomics; 2015; 7(6):897-910. PubMed ID: 26479311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells.
    Ueno Y; Sakurai H; Tsunoda S; Choo MK; Matsuo M; Koizumi K; Saiki I
    Int J Cancer; 2008 Jul; 123(2):340-347. PubMed ID: 18398842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
    Kurtze I; Sonnemann J; Beck JF
    Oncol Rep; 2011 Apr; 25(4):1021-9. PubMed ID: 21271222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
    Fujii K; Suzuki N; Jimura N; Idogawa M; Kondo T; Iwatsuki K; Kanekura T
    J Dermatol Sci; 2018 Apr; 90(1):82-89. PubMed ID: 29395577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
    Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
    Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
    Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
    Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
    Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
    BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
    Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
    Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells.
    Ji M; Lee EJ; Kim KB; Kim Y; Sung R; Lee SJ; Kim DS; Park SM
    Oncol Rep; 2015 May; 33(5):2299-308. PubMed ID: 25813246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA; Bok I; Smallridge RC; Copland JA
    Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the Effects of Valproic Acid Treatment on Cell Survival and Epithelial-Mesenchymal Transition-Related Features of Human Gastric Cancer Cells.
    Jahani M; Khanahmad H; Nikpour P
    J Gastrointest Cancer; 2021 Jun; 52(2):676-681. PubMed ID: 32621111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung.
    Chang TH; Szabo E
    Clin Cancer Res; 2002 Apr; 8(4):1206-12. PubMed ID: 11948134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
    Di Gennaro E; Bruzzese F; Pepe S; Leone A; Delrio P; Subbarayan PR; Avallone A; Budillon A
    Cancer Biol Ther; 2009 May; 8(9):782-91. PubMed ID: 19270508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.
    Lund CV; Popkov M; Magnenat L; Barbas CF
    Mol Cell Biol; 2005 Oct; 25(20):9082-91. PubMed ID: 16199884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.
    Koyama M; Izutani Y; Goda AE; Matsui TA; Horinaka M; Tomosugi M; Fujiwara J; Nakamura Y; Wakada M; Yogosawa S; Sowa Y; Sakai T
    Clin Cancer Res; 2010 Apr; 16(8):2320-32. PubMed ID: 20371690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
    Shindo Y; Arai W; Konno T; Kohno T; Kodera Y; Chiba H; Miyajima M; Sakuma Y; Watanabe A; Kojima T
    Histochem Cell Biol; 2021 Jun; 155(6):637-653. PubMed ID: 33974136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
    PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.